Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Centene (CNC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX) and Centene (CNC).
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurocrine (NBIX)
Wedbush analyst Laura Chico maintained a Buy rating on Neurocrine today and set a price target of $166.00. The company’s shares closed last Monday at $132.48.
According to TipRanks.com, Chico is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $184.05, which is a 40.6% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $185.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Centene (CNC)
In a report released yesterday, Scott Fidel from Goldman Sachs maintained a Sell rating on Centene, with a price target of $32.00. The company’s shares closed last Monday at $35.40.
According to TipRanks.com, Fidel is a 5-star analyst with an average return of
Centene has an analyst consensus of Hold, with a price target consensus of $42.38, a 20.4% upside from current levels. In a report released today, Bank of America Securities also maintained a Sell rating on the stock with a $34.00 price target.
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine price target raised to $166 from $151 at Wedbush
- Neurocrine price target raised to $199 from $190 at BofA
- Balanced Risk-Reward After Soleno Acquisition Supports Neutral Stance on Neurocrine
- Neurocrine price target raised to $215 from $192 at H.C. Wainwright
- Neurocrine price target raised to $166 from $151 at Baird
